SOURCE: INC Research

INC Research

September 09, 2010 07:00 ET

INC Research Enhances Infectious Disease Therapeutic Team With C. Jo White, M.D.

Seasoned Professional Joins as Vice President, Clinical Development

RALEIGH, NC--(Marketwire - September 9, 2010) -  INC Research ®, Inc., a therapeutically focused contract research organization (CRO) with a process for delivering reliable results, is pleased to welcome C. Jo White, M.D. as vice president, clinical development of Infectious Diseases to maintain the company's therapeutic leadership in infectious disease research. She will advise on clinical trial design and execution, as well as global regulatory compliance for vaccine drug development programs.

"There continues to be a worldwide fight against infectious disease, and drug developers are partnering with us to intelligently move their compounds through the clinical trials process," said John Potthoff, COO of INC Research. "Jo is an incredible asset to our Infectious Disease team, as her clinical vaccine experience speaks for itself."

Dr. White has 23 years of clinical and product development experience in the pharmaceutical industry with a focus in vaccine development, primarily in the areas of infectious diseases. She has held senior level clinical and medical affairs positions with several pharmaceutical companies, including Aviron (now MedImmune/AstraZeneca), North American Vaccine (now Baxter), Wyeth (now Pfizer), and VGX Pharmaceuticals (now Inovio Biomedical). Dr. White has designed and conducted more than 50 Phase I through IV trials, filed numerous Biologics License Applications/Marketing Authorization Applications/sNDAs, and has obtained regulatory approval for five different vaccines and drugs in both the United States and Europe. In addition to her private sector experience, Dr. White also brings public sector experience to INC Research, having trained at the NIAID, NIH. Dr. White also currently serves as a consultant for the Malaria Vaccine Consultants Group (MVCG) Meeting as part of the U.S. National Institute of Allergy and Infectious Diseases' (NIAID) continued dedication to malaria vaccine development efforts. She was trained in microbiology at University of Texas, where she graduated Summa Cum Laude. Dr. White holds an M.D. from Baylor College of Medicine with Alpha Omega Alpha honors. She is board certified in both Internal Medicine and Infectious Diseases.

INC Research's Infectious Disease team has experience in all stages and functions associated with the development of anti-infectives. Applying the Trusted Process® methodology on trials for companies focused on vaccine development, the global CRO delivers trusted results on time and on budget for both pediatric and adult trials of all levels of complexity and includes work in the areas of anti-bacterials, anti-virals, anti-fungals and vaccines.

INC Research will be exhibiting at ICAAC 2010 from Sept. 12-14 at booth #1036. For more information about its infectious disease experience, case studies and services, click here.

About INC Research® Inc.
INC Research is a therapeutically focused contract research organization with a high performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to INC Research for a complete range of customized Phase I through Phase IV programs in therapeutic areas of specialty, and in innovative pediatric and women's health trials. The company's The Trusted Process® methodology and therapeutic foresight leads customers to more confident, better-informed drug and device development decisions. INC Research is headquartered in Raleigh, North Carolina. For more information please visit www.incresearch.com.

Contact Information